At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
pazopanib hydrochloride +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of GW786034 (Pazopanib) in Asian Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
In Brief
A Phase 2 clinical trial evaluating pazopanib hydrochloride, pharmacological study, and 1 other intervention for Recurrent Lymphoepithelioma of the Nasopharynx and 3 related conditions. Completed, enrolled 33 participants across 3 sites.
Detailed Summary
This phase II trial studies the side effects and how well pazopanib hydrochloride works in treating patients with stage IV or recurrent nasopharyngeal cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Lymphoepithelioma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx
CountriesSingapore
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartAug 2007
Primary CompletionApr 2010
Study CompletionAug 2010
TodayJul 2026
First PostedMar 30, 2007
Enrollment StartAug 1, 2007
Primary CompletionApr 1, 2010
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 19.3 years ago
Interventions
pazopanib hydrochloridedrug
Given PO
pharmacological studyother
Correlative studies
computed tomographyprocedure
Correlative studies